Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus

DOI Web Site Web Site 2 References
  • MORITA MASARU
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • IKEBE MASAHIKO
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • KAGAWA MASAKI
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • NAKAJI YU
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • SUGIYAMA MASAHIKO
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • YOSHIDA DAISUKE
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • OTA MITSUHIKO
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • IGUCHI TOMOHIRO
    Department of Hepato-Biliary Pancreatic Surgery, National Kyushu Cancer Center
  • SUGIMACHI KEISHI
    Department of Hepato-Biliary Pancreatic Surgery, National Kyushu Cancer Center
  • KUNITAKE NAONOBU
    Department of Radiology, National Kyushu Cancer Center
  • SAEKI HIROSHI
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University
  • OKI EIJI
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University
  • OHGA SAIJI
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • TOH YASUSHI
    Department of Gastroenterological Surgery, National Kyushu Cancer Center
  • MAEHARA YOSHIHIKO
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • 食道癌に対する治療の動向とハイパーサーミアの役割

Search this article

Abstract

Squamous cell carcinoma of the esophagus (ESCC) is a fairly aggressive disease with a poor prognosis. Surgical resection has been the gold standard of treatment for localized ESCC. However, this carcinoma is fairly sensitive to radiation, as well as chemotherapeutic agents such as cisplatin and 5-fluorouracil. Based on clinical trials conducted mainly by the Japan Clinical Oncology Group (JCOG), preoperative chemotherapy is regarded as the standard treatment for resectable ESCC in Japan. We have applied hyperthermia to ESCC mainly as a preoperative treatment associated with chemoradiotherapy since it has been experimentally proven to enhance the anti-tumor effects of chemotherapeutic agents and irradiation. The long-term survival as well as histological effectiveness was reported to be better in patients who received preoperative hyperthermochemoradiotherapy (HCR) than in those who received preoperative chemoradiotherapy (CRT). Definitive CRT is frequently performed even for resectable ESCC, and salvage treatment for either remnant or recurrent diseases remains an important clinical problem. We have applied hyperthermia simultaneously with chemotherapy as a salvage treatment for such patients, and complete response as well as stable disease was achieved in several patients. Hyperthermia is a promising modality as a salvage treatment and has recently been incorporated into regimens including taxanes. Potential enhancement of hyperthermia with certain drugs should be experimentally evaluated, and the clinical application of hyperthermia may be warranted with other newly-developed regimens.

Journal

  • Thermal Medicine

    Thermal Medicine 33 (3), 63-73, 2017

    Japanese Society for Thermal Medicine

References(2)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top